A multicenter randomized phase III trial of domestic product of rmhTNF in the treatment of non-small cell lung cancer

• Published in: Zhongguo fei ai za zhi 2003-08, Vol.6 (4), p.264
• Main Authors: Zhou, Qinghua, Yan, Xi, Ren, Li, Li, Lu, Qiu, Meng, Yang, Yuqiong, Luo, Deyun, Huang, Wenxia, Liu, Luming, Chen, Zhen, Meng, Zhiqiang, Wang, Yajie, Fu, Qiang, Xu, Yang, Yang, Linjun, Li, Mingzhong, Li, Enxiao, Li, Yi, Yao, Yu, Zhang, Xiangfu, Liu, Xing, Lu, Huishan, Zhang, Maohong, Wang, Xiuwen, Yu, Xuejun, Qin, Fengzhan, Zheng, Rongsheng, Chen, Yuqing, Bi, Minghong
• Format: Article
• Language: Chinese
• Subjects: Chemotherapy; Entrepreneurs; Lung cancer
• ISSN: 1009-3419; 1999-6187
• DOI: 10.3779/cjlc.v6i4.2780

To evaluate and compare the effects and toxicity of the domestic product of recombinant mutant human tumor necrosis factor (rmhTNF) combined with chemotherapy and chemotherapy alone in the treatment of patients with non-small cell lung cancer (NSCLC). Two hundred patients with NSCLC in multicenter were randomly devided into trial group (150 cases) and control group (50 cases). Chemotherapy with CAP regimen was given to the patients. Meanwhile, rmhTNF injection of 4×10⁶U/m² was also given from the 1st to 7th days, the 11th to 17th days on the chemotherapy cycle in the trial group. The control patients received chemotherapy alone. Twenty-one days were as a cycle, 2 cycles were given to each patient. The chemotherapeutic effects and toxicity were observed and compared between the two groups after the therapy. of the 200 patients, 5 cases in the trial group and 3 cases in the control group were out of the trial because of economy. The other 192 cases (145 cases in the trial group and 47 cases in the control group